0.9779
price down icon2.21%   -0.0221
after-market After Hours: .95 -0.0279 -2.85%
loading
Biofrontera Inc stock is traded at $0.9779, with a volume of 927.36K. It is down -2.21% in the last 24 hours and up +1.86% over the past month. Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
See More
Previous Close:
$1.00
Open:
$0.99
24h Volume:
927.36K
Relative Volume:
0.38
Market Cap:
$5.71M
Revenue:
$34.07M
Net Income/Loss:
$-20.13M
P/E Ratio:
-0.0571
EPS:
-17.1162
Net Cash Flow:
$-24.90M
1W Performance:
+11.63%
1M Performance:
+1.86%
6M Performance:
-43.15%
1Y Performance:
-78.02%
1-Day Range:
Value
$0.91
$1.06
1-Week Range:
Value
$0.7946
$2.22
52-Week Range:
Value
$0.61
$4.39

Biofrontera Inc Stock (BFRI) Company Profile

Name
Name
Biofrontera Inc
Name
Phone
781-245-1325
Name
Address
120 PRESIDENTIAL WAY,, WOBURN
Name
Employee
85
Name
Twitter
Name
Next Earnings Date
2024-11-13
Name
Latest SEC Filings
Name
BFRI's Discussions on Twitter

Biofrontera Inc Stock (BFRI) Latest News

pulisher
Nov 01, 2024

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance

Nov 01, 2024
pulisher
Oct 31, 2024

Biofrontera Announces Promising Phase 3 Study Results - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Biofrontera reports breakthrough in skin cancer treatment - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Biofrontera Inc. Announces Highly Significant Results In - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan

Oct 31, 2024
pulisher
Oct 23, 2024

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance

Oct 23, 2024
pulisher
Oct 15, 2024

Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia

Oct 15, 2024
pulisher
Oct 14, 2024

Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India

Oct 14, 2024
pulisher
Oct 14, 2024

Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire

Oct 14, 2024
pulisher
Oct 14, 2024

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan

Oct 14, 2024
pulisher
Oct 08, 2024

BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Oct 08, 2024
pulisher
Oct 07, 2024

Mass. Biotech Receives FDA Approval - Streetwise Reports

Oct 07, 2024
pulisher
Oct 07, 2024

Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India

Oct 07, 2024
pulisher
Oct 07, 2024

What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com

Oct 07, 2024
pulisher
Oct 07, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times

Oct 07, 2024
pulisher
Oct 07, 2024

FDA approves expanded use of Biofrontera's Ameluz for AK By Investing.com - Investing.com UK

Oct 07, 2024
pulisher
Oct 07, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire

Oct 07, 2024
pulisher
Oct 07, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - StockTitan

Oct 07, 2024
pulisher
Oct 04, 2024

BFRI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Oct 04, 2024
pulisher
Oct 04, 2024

Ratio Examination: Biofrontera Inc (BFRI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 04, 2024
pulisher
Oct 03, 2024

Tilray Brands (TLRY) Stock Surges Amidst Market Volatility - GuruFocus.com

Oct 03, 2024
pulisher
Oct 02, 2024

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times

Oct 02, 2024
pulisher
Oct 02, 2024

Biofrontera Second Quarter 2024 Earnings: €0.023 loss per share (vs €0.12 profit in 2Q 2023) - Yahoo Finance

Oct 02, 2024
pulisher
Oct 01, 2024

Five PDUFA dates on FDA’s October agenda - BioCentury

Oct 01, 2024
pulisher
Oct 01, 2024

Photodynamic Therapy Market Share, Trends, Size, Major Players And Forecast To 2033 - WhaTech

Oct 01, 2024
pulisher
Sep 30, 2024

Biotech Stocks Facing FDA Decision In October 2024 - Nasdaq

Sep 30, 2024
pulisher
Sep 28, 2024

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St

Sep 28, 2024
pulisher
Sep 25, 2024

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

Taking on analysts’ expectations and winning: Biofrontera Inc (BFRI) - SETE News

Sep 24, 2024
pulisher
Sep 23, 2024

Trading Day Triumph: Biofrontera Inc (BFRI) Ends at 1.28, a 0.00 Surge/Plunge - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

A stock that deserves closer examination: Biofrontera Inc (BFRI) - US Post News

Sep 23, 2024
pulisher
Sep 20, 2024

Leidos Holdings, Inc. (NYSE:LDOS) Shares Sold by Tredje AP fonden - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

Market Insight: Biofrontera Inc (BFRI)’s Notable Gain, Closing at 1.29 - The Dwinnex

Sep 19, 2024
pulisher
Sep 13, 2024

Taking the lead: Biofrontera Inc (BFRI) - SETE News

Sep 13, 2024
pulisher
Sep 12, 2024

Biofrontera Inc (BFRI) Stock: From Low to High in 52 Weeks - The InvestChronicle

Sep 12, 2024
pulisher
Sep 09, 2024

Biofrontera Inc (BFRI) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News

Sep 09, 2024
pulisher
Sep 04, 2024

Biofrontera Inc (BFRI) Stock: Navigating a Year of Stock Volatility - The InvestChronicle

Sep 04, 2024
pulisher
Sep 02, 2024

Biofrontera Inc (BFRI) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Biofrontera Inc (BFRI)’s results reveal risk - US Post News

Sep 02, 2024
pulisher
Aug 28, 2024

Louisiana State Employees Retirement System Acquires 700 Shares of HNI Co. (NYSE:HNI) - Defense World

Aug 28, 2024
pulisher
Aug 28, 2024

A SPAC II Acquisition Corp. (NASDAQ:ASCB) Sees Large Decrease in Short Interest - Defense World

Aug 28, 2024
pulisher
Aug 19, 2024

Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Aug 19, 2024
pulisher
Aug 18, 2024

Biofrontera (NASDAQ:BFRI) Stock Rating Reaffirmed by Benchmark - Defense World

Aug 18, 2024
pulisher
Aug 17, 2024

Biofrontera Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Aug 17, 2024

Biofrontera Inc Stock (BFRI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$12.67
price up icon 0.88%
$114.96
price down icon 0.42%
$89.24
price up icon 3.56%
$58.48
price down icon 0.36%
$121.53
price up icon 0.83%
$11.61
price up icon 1.40%
Cap:     |  Volume (24h):